BridgeBio Pharma Inc. (BBIO) Tops Q2 EPS by 30c

BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q2 EPS of ($0.66), $0.30 better than the analyst estimate of ($0.96). Revenue for the quarter came in at $54.02 million versus the consensus estimate of $29.12 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Mercury Systems (MRCY) Misses Q4 EPS by 2c
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance